Newsroom | 4971 results

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the “Issuers”), have closed the upsized offering of €675 million aggregate principal amount of senior secured floating rate notes due 2031 (the “Notes”). In addition, the compa...

TORONTO--(BUSINESS WIRE)--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that Alcon Canada has been certified as a Top Employer in Canada by the Top Employers Institute, a recognized authority on identifying excellence in people practices and workplace culture. Being certified as a Top Employer showcases Alcon Canada’s commitment to building a better world of work through exceptional HR policies and forward-thinking people practices. This recog...

TORONTO--(BUSINESS WIRE)--Alcon, le chef de file mondial en soins oculaires qui se consacre à aider les gens à voir avec clarté, a annoncé aujourd’hui qu’Alcon Canada a reçu la certification de meilleur employeur au Canada décernée par le Top Employers Institute, l’autorité de référence mondiale en matière d’évaluation de l’excellence des pratiques RH et de la culture du milieu de travail. Recevoir la certification de meilleur employeur démontre l’engagement d’Alcon Canada à créer un monde du t...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible au PEA-PME), société biopharmaceutique spécialisée dans le développement et la commercialisation de thérapies géniques innovantes pour les maladies neurodégénératives rétiniennes et les troubles du système nerveux central, annonce aujourd’hui le transfert réussi de la phase amont du procédé de fabrication de LUMEVOQ®, son produit candidat de thérapie génique destiné au traitement de la n...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the successful transfer of the upstream phase of the manufacturing process for LUMEVOQ®, the Company’s gene therapy candidate product for the rare mitochondrial disease Leber Hereditary Optic Neuropath...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received European Union (EU) Medical Device Regulation (MDR) certification for iStent infinite®, along with several of its other leading micro-invasive glaucoma surgery (MIGS) technologies, including iStent inject® W. Glaukos’ iStent® trabecular...

DUBLIN--(BUSINESS WIRE)--The "Acute Ocular Pain Market - A Global and Regional Analysis: Focus on Indication and Region - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The global acute ocular pain market driven by the increasing prevalence of ocular conditions, an aging population, and technological advancement. The acute ocular pain indicates to a sudden onset of discomfort, pain, or distress in the eye. It can be varied depend on the intensity a...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that Deborah Andrews has been appointed Chief Financial Officer, effective June 25, 2025. Ms. Andrews has served as Interim CFO since March 2025, and she previously served as STAAR’s CFO from 2007-2013 and 2017-2020. “Deborah has blended seamlessly with the leadership team, and we quick...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it will celebrate the 10th anniversary of its Initial Public Offering (IPO) listing on the New York Stock Exchange (NYSE) by ringing The Closing Bell at 4:00 p.m. ET today, Wednesday, June 25, 2025. "Ringing the NYSE closing bell today is a proud and hu...

YOKNEAM ILLIT, Israel--(BUSINESS WIRE)--ForSight Robotics secures $125M Series B funding, led by Eclipse, to tackle global vision crisis and perform robotic cataract surgery clinical trials....